# Synta Pharmaceuticals Corp. clinical trials: 25 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 25 trials with Synta Pharmaceuticals Corp. as lead sponsor, 0 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Synta Pharmaceuticals Corp.: 25 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email.

Buy: https://specstream.ai/data/clinical-trials/company/synta-pharmaceuticals-corp

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 25
- Recruiting or not yet: 0
- Read on: November 19, 2026

## Trials

The 25 newest of 25, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| February 25, 2013 | NCT01798485 | A Phase 3 Study of Ganetespib in Combination With Docetaxel Versus Docetaxel Alone in Patients With Advanced NSCLC | Synta Pharmaceuticals Corp. | Phase 3 | Terminated | Non-Small-Cell Lung Adenocarcinoma, Non-small Cell Lung Cancer Stage IIIB, Non-small Cell Lung Cancer Stage IV... | 696 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01798485) |
| September 3, 2012 | NCT01677455 | An Open-Label Multicenter Phase 2 Window of Opportunity Study Evaluating Ganetespib in Women With Breast Cancer | Synta Pharmaceuticals Corp. | Phase 2 | Completed | Breast Cancer, HER-2 Positive Breast Cancer, Triple Negative Breast Cancer, ER/Progressive Response (PR) + Refractory... | 51 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01677455) |
| March 23, 2012 | NCT01562015 | A Study of Ganetespib in Subjects With ALK-Positive Non-Small-Cell Lung Cancer (NSCLC) | Synta Pharmaceuticals Corp. | Phase 2 | Completed | Non Small Cell Lung Cancer | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01562015) |
| May 5, 2011 | NCT01348126 | Study of Ganetespib (STA-9090) + Docetaxel in Advanced Non Small Cell Lung Cancer | Synta Pharmaceuticals Corp. | Phase 2/3 | Terminated | Non-small Cell Lung Cancer Stage IIIB, Non-small Cell Lung Cancer Stage IV, Non-small Cell Lung Cancer Metastatic | 385 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01348126) |
| January 21, 2011 | NCT01280786 | Study Elesclomol Sodium in Patients With Relapsed or Refractory Acute Myeloid Leukemia | Synta Pharmaceuticals Corp. | Phase 1 | Unknown | Acute Myeloid Leukemia | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01280786) |
| August 17, 2010 | NCT01183364 | A Dose Escalation Study of STA-9090 and Docetaxel in Patients With Solid Tumors | Synta Pharmaceuticals Corp. | Phase 1 | Completed | Solid Tumor Malignancies | 27 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01183364) |
| December 25, 2009 | NCT01039519 | A Study Evaluating STA-9090 in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor (GIST) | Synta Pharmaceuticals Corp. | Phase 2 | Completed | Gastrointestinal Stromal Tumor | 27 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01039519) |
| December 14, 2009 | NCT01031225 | A Study of the HSP90 Inhibitor, STA-9090 in Subjects With Stage IIIB or IV Non-Small Cell Lung Cancer (NSCLC) | Synta Pharmaceuticals Corp. | Phase 2 | Completed | Non Small Cell Lung Cancer | 113 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01031225) |
| August 25, 2009 | NCT00964873 | A Phase 1 Study of the HSP90 Inhibitor, STA-9090 in Subjects With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Blast-phase... | Synta Pharmaceuticals Corp. | Phase 1 | Completed | Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Blast-phase Chronic Myelogenous Leukemia, AML, ALL, CML | 29 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00964873) |
| March 10, 2009 | NCT00858572 | STA-9090 for Treatment of AML, CML, MDS and Myeloproliferative Disorders | Synta Pharmaceuticals Corp. | Phase 1 | Completed | AML, CML, MDS, Myeloproliferative Disorders | 31 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00858572) |
| January 22, 2009 | NCT00827203 | A Safety Study to Determine the Maximum Tolerated Dose of Elesclomol Sodium in Patients With Solid Tumors | Synta Pharmaceuticals Corp. | Phase 1 | Suspended | Metastatic Solid Tumors | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00827203) |
| December 15, 2008 | NCT00808418 | A Study to Determine the Maximum Tolerated Dose of Elesclomol Sodium Given With a Fixed Dose of Docetaxel and Prednisone in Patients With... | Synta Pharmaceuticals Corp. | Phase 1 | Completed | Prostate Cancer | 34 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00808418) |
| June 2, 2008 | NCT00688116 | Study of STA-9090, Administered Twice-Weekly in Patients With Solid Tumors | Synta Pharmaceuticals Corp. | Phase 1 | Unknown | Solid Tumors | 45 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00688116) |
| June 2, 2008 | NCT00687934 | Study of STA-9090, Administered Once-Weekly in Patients With Solid Tumors | Synta Pharmaceuticals Corp. | Phase 1 | Completed | Solid Tumors | 53 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00687934) |
| March 25, 2008 | NCT00642629 | A Randomized, Double-blind, Placebo-controlled Clinical Study of the Oral IL-12/23 Inhibitor, STA-5326 Mesylate, Administered to Patients... | Synta Pharmaceuticals Corp. | Phase 2 | Completed | Active, Moderate to Severe Rheumatoid Arthritis | 35 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00642629) |
| August 30, 2007 | NCT00522834 | Elesclomol (STA-4783) With Paclitaxel Versus Paclitaxel Alone in Melanoma | Synta Pharmaceuticals Corp. | Phase 3 | Terminated | Melanoma | 630 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00522834) |
| January 13, 2006 | NCT00276913 | A Phase I Study of STA-5312 in Subjects With Advanced or Metastatic Solid Tumors | Synta Pharmaceuticals Corp. | Phase 1 | Completed | Advanced or Metastatic Solid Tumors | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00276913) |
| October 7, 2005 | NCT00234741 | Study of STA-5326 Mesylate in Patients With Moderate to Severe Crohn's Disease | Synta Pharmaceuticals Corp. | Phase 2 | Completed | Crohn's Disease | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00234741) |
| August 30, 2005 | NCT00138840 | Study of STA-5326 Mesylate in Patients With Moderate to Severe Crohn's Disease | Synta Pharmaceuticals Corp. | Phase 2 | Completed | Crohn's Disease | 282 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00138840) |
| July 23, 2004 | NCT00087997 | A Study of STA-4783 in Combination With Weekly Paclitaxel for Treatment of Patients With Soft Tissue Sarcomas | Synta Pharmaceuticals Corp. | Phase 2 | Completed | Soft Tissue Sarcoma | 80 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00087997) |
| July 21, 2004 | NCT00088114 | STA-4783 and Paclitaxel for Treatment of Solid Tumors | Synta Pharmaceuticals Corp. | Phase 1 | Completed | Neoplasms | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00088114) |
| July 21, 2004 | NCT00088101 | STA-5312 Administered on Alternate Weekdays Every Two Weeks to Patients With Hematologic Malignancies and Patients With Solid Tumors | Synta Pharmaceuticals Corp. | Phase 1 | Completed | Hematological Malignancies, Leukemia, Lymphoma, Metastatic or Unresectable Solid Tumors | 42 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00088101) |
| July 21, 2004 | NCT00088088 | STA-4783 in Combination With Paclitaxel and Carboplatin for the Treatment of Chemotherapy Naive Patients With Stage IIIB/IV Non Small Cell... | Synta Pharmaceuticals Corp. | Phase 1/2 | Completed | Stage IIIB Non-Small Cell Lung Cancer, Stage IV Non-Small Cell Lung Cancer | 86 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00088088) |
| July 21, 2004 | NCT00088062 | STA-5326 in Crohn's Disease Patients | Synta Pharmaceuticals Corp. | Phase 1/2 | Completed | Crohn's Disease | 48 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00088062) |
| June 10, 2004 | NCT00084214 | STA-4783/Paclitaxel or Paclitaxel Alone in Melanoma | Synta Pharmaceuticals Corp. | Phase 1/2 | Completed | Melanoma | 103 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00084214) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 11 |
| Phase 1/2 | 3 |
| Phase 2 | 8 |
| Phase 2/3 | 1 |
| Phase 3 | 2 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 19 |
| Terminated | 3 |
| Unknown | 2 |
| Suspended | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Neoplasm Metastasis | 6 |
| Carcinoma, Non-Small-Cell Lung | 5 |
| Neoplasms | 5 |
| Crohn Disease | 3 |
| Lung Neoplasms | 2 |
| Melanoma | 2 |
| Hematologic Neoplasms | 2 |
| Leukemia, Myeloid, Acute | 2 |
| Leukemia | 2 |
| Gastrointestinal Stromal Tumors | 1 |
| Sarcoma | 1 |
| Prostatic Neoplasms | 1 |
| Myeloproliferative Disorders | 1 |
| Breast Neoplasms | 1 |
| Triple Negative Breast Neoplasms | 1 |
| Motor Activity | 1 |
| Recurrence | 1 |
| Lymphoma | 1 |
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 |
| Blast Crisis | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Pharmaceutical companies in the United States](https://specstream.ai/data/businesses/pharmaceutical-companies/united-states)
- [Acupuncture clinics in the United States](https://specstream.ai/data/businesses/acupuncture-clinics/united-states)
- [Nicaraguan restaurants in the United States](https://specstream.ai/data/businesses/nicaraguan-restaurants/united-states)
- [Dentistry schools in the United States](https://specstream.ai/data/businesses/dentistry-schools/united-states)
- [Tools wholesalers in the United States](https://specstream.ai/data/businesses/tools-wholesalers/united-states)
- [Land surveyors in the United States](https://specstream.ai/data/businesses/land-surveyors/united-states)
